TORONTO-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (ATE.V) announced today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346.
The results support the Company's earlier communication that ATB-346 may be effective at much lower doses than previously expected, and that once daily dosing may be effective. Together, over 600 blood samples from its Phase 1 human clinical trial were independently analysed to assess the ability of ATB-346, at doses ranging from 25 to 1000 mg, to inhibit the enzyme "cyclooxygenase" (COX). The reduction of pain and inflammation by non-steroidal anti-inflammatory drugs (NSAIDs) is attributed to their ability to inhibit COX activity.
Substantial inhibition of COX was observed at doses of ATB-346 as low as 75 mg, and the inhibition was maintained for 24 hours.
The Company continues to conduct validation studies, and will report to the market as they proceed.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for severe acute pain.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Important Note on Forward Looking Statements
Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.